CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 129 enrolled
Drug / intervention
Urokinase +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00799968
NCT00799968Phase 4Completed
CompareCT.gov

Efficacy and Safety Evaluation of 12-h and 2-h Urokinase Regimes in the Treatment of Pulmonary Thromboembolism: A Multi-Center, Randomized Controlled Trial in China

Beijing Chao Yang Hospital·interventional·Posted Dec 1, 2008·Updated Dec 1, 2008

In Brief

A Phase 4 clinical trial evaluating Urokinase for Pulmonary Embolism and Thromboembolism. Completed, enrolled 129 participants across 31 sites.

Detailed Summary

Comparative trials of urokinase (UK) for 12 hours（UK-12h）or 24 hours (UK-24h) have produced similar results in acute pulmonary thromboembolism (PTE) thrombolysis. It is unclear whether the infusion time can be reduced further. The aim of this study was to investigate the efficacy and safety of weight adjusted dosage of UK-2h (20 000 IU/Kg) regime with the Uk-12h regime in selected patients with PTE in Chinese population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPulmonary Embolism, Thromboembolism
CountriesChina
Collaborators--

Timeline

Phase 4CompletedFinished
20022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 1, 2008
Enrollment StartJun 1, 2002
Primary CompletionFeb 1, 2006
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 17.6 years ago

Interventions

Urokinasedrug

UK,bolus 4 400 U/kg followed by intravenous 2 200 U/kg•h for 12 hours

Urokinasedrug

UK,20 000U/kg continuously intravenous infusion for 2 hours